Nasri Khadijeh, Jamilian Mehri, Rahmani Elham, Bahmani Fereshteh, Tajabadi-Ebrahimi Maryam, Asemi Zatollah
Endocrinology and Metabolism Research Center, Arak University of Medical Sciences, Arak, Iran.
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, IR, Iran.
BMC Endocr Disord. 2018 Apr 12;18(1):21. doi: 10.1186/s12902-018-0248-0.
To our knowledge, no reports are available indicating the effects of synbiotic supplementation on hormonal status, biomarkers of inflammation and oxidative stress in subjects with polycystic ovary syndrome (PCOS). This research was done to assess the effects of synbiotic supplementation on hormonal status, biomarkers of inflammation and oxidative stress in subjects with PCOS.
This randomized double-blind, placebo-controlled trial was conducted on 60 subjects diagnosed with PCOS according to the Rotterdam criteria. Subjects were randomly assigned into two groups to take either synbiotic (n = 30) or placebo (n = 30) for 12 weeks. Endocrine, inflammation and oxidative stress biomarkers were quantified at baseline and after the 12-week intervention.
After the 12-week intervention, compared with the placebo, synbiotic supplementation significantly increased serum sex hormone-binding globulin (SHBG) (changes from baseline in synbiotic group: + 19.8 ± 47.3 vs. in placebo group: + 0.5 ± 5.4 nmol/L, p = 0.01), plasma nitric oxide (NO) (changes from baseline in synbiotic group: + 5.5 ± 4.8 vs. in placebo group: + 0.3 ± 9.1 μmol/L, p = 0.006), and decreased modified Ferriman Gallwey (mF-G) scores (changes from baseline in synbiotic group: - 1.3 ± 2.5 vs. in placebo group: - 0.1 ± 0.5, p = 0.01) and serum high-sensitivity C-reactive protein (hs-CRP) (changes from baseline in synbiotic group: - 950.0 ± 2246.6 vs. in placebo group: + 335.3 ± 2466.9 ng/mL, p = 0.02). We did not observe any significant effect of synbiotic supplementation on other hormonal status and biomarkers of oxidative stress.
Overall, synbiotic supplementation for 12 weeks in PCOS women had beneficial effects on SHBG, mFG scores, hs-CRP and NO levels, but did not affect other hormonal status and biomarkers of oxidative stress.
This study was retrospectively registered in the Iranian website ( www.irct.ir ) for registration of clinical trials ( IRCT201509115623N53 ), on 2015-09-27.
据我们所知,尚无关于合生制剂补充对多囊卵巢综合征(PCOS)患者激素状态、炎症和氧化应激生物标志物影响的报告。本研究旨在评估合生制剂补充对PCOS患者激素状态、炎症和氧化应激生物标志物的影响。
本随机双盲、安慰剂对照试验对60例根据鹿特丹标准诊断为PCOS的受试者进行。受试者被随机分为两组,分别服用合生制剂(n = 30)或安慰剂(n = 30),为期12周。在基线和12周干预后对内分泌、炎症和氧化应激生物标志物进行定量分析。
12周干预后,与安慰剂组相比,合生制剂补充显著增加血清性激素结合球蛋白(SHBG)(合生制剂组较基线变化:+19.8±47.3 vs. 安慰剂组:+0.5±5.4 nmol/L,p = 0.01)、血浆一氧化氮(NO)(合生制剂组较基线变化:+5.5±4.8 vs. 安慰剂组:+0.3±9.1 μmol/L,p = 0.006),并降低改良Ferriman Gallwey(mF-G)评分(合生制剂组较基线变化:-1.3±2.5 vs. 安慰剂组:-0.1±0.5,p = 0.01)和血清高敏C反应蛋白(hs-CRP)(合生制剂组较基线变化:-950.0±2246.6 vs. 安慰剂组:+335.3±2466.9 ng/mL,p = 0.02)。我们未观察到合生制剂补充对其他激素状态和氧化应激生物标志物有任何显著影响。
总体而言,PCOS女性补充合生制剂12周对SHBG、mFG评分、hs-CRP和NO水平有有益影响,但不影响其他激素状态和氧化应激生物标志物。
本研究于2015年9月27日在伊朗临床试验注册网站(www.irct.ir)进行回顾性注册(IRCT201509115623N53)。